NPPA notifies lower MRPs for 543 brands of anti-cancer medicines from 9 November
Published · AiPYQs Editorial · Event date 28 Oct 2026
The National Pharmaceutical Pricing Authority released revised, lower MRPs for 543 anti-cancer drug brands effective 9 November 2026, following trade margin rationalisation on 137 non-scheduled drugs.
What happened
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, released a list of 543 brands of anti-cancer medicines with revised Maximum Retail Prices on 28 October 2026. The new prices apply from 9 November 2026.
Key points
- Follows NPPA's decision of 17 October 2026 to apply Trade Margin Rationalisation to 137 non-scheduled anti-cancer drugs.
- Covers immunotherapy medicines, denosumab, pegfilgrastim and bevacizumab.
- Example cited: the MRP of a 10-tablet pack of an anastrozole brand fell from ₹695.76 to ₹73.
Why it matters
Drug pricing regulation and health policy are regular topics in governance and health sections.
Sources
#NPPA#anti-cancer drugs#drug pricing#trade margin rationalisation